Author

Motoyuki Tsuda

Oregon Health & Science UniversityORCID 0000-0003-2873-1449Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell-cell communication· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

Rosalie C. SearsiD· 5 shared Carl PelziD· 3 shared Colin J. DanieliD· 3 shared Hayley ZimnyiD· 3 shared Jennifer R. EngiD· 3 shared Jonathan Robert BrodyiD· 3 shared Patrick Joseph WorthiD· 3 shared Trent WaughiD· 3 shared

Activity by Year

2025-2026 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

Rosalie C. SearsORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 29, 2026

Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells

Kevin Hawthorne, Jennifer R. Eng, Motoyuki Tsuda…·Rosalie C. Sears

The paper identifies subtype-intermediate progenitor cells in pancreatic cancer with distinct epigenetic profiles linked to clinical outcomes and lineage reprogramming.

DOI 10.64898/2026.09.28.754674

humanscATAC-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 15, 2025

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel…·Rosalie C. Sears

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

DOI 10.64898/2025.12.12.693851

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 14, 2025

Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model

Isabel A. English, Patrick Joseph Worth, Kevin Hawthorne…·Rosalie C. Sears

This study develops a novel pancreatic cancer mouse model by expressing Myc and mutant Kras in adult acinar cells, showing metastasis and therapeutic resistance similar to human PDAc.

5 citations

mouseexperimental assay

𝕏 PostBluesky

Cell BiologybioRxivPreprintMay 13, 2025

PIN1 Drives Cellular Plasticity and Immune Modulation in Chronic Pancreatitis

Vidhi M. Shah, Alexandra Q. Bartlett, Canping Chen…·Rosalie C. Sears

This study shows PIN1 promotes cellular plasticity and immune changes in chronic pancreatitis, with genetic or pharmacological inhibition reducing disease severity.

DOI 10.1101/2025.05.13.653850

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 11, 2025

Clonal Heterogeneity in Human Pancreatic Ductal Adenocarcinoma and Its Impact on Tumor Progression

Despoina Kalfakakou, Daniel C. Cameron, Emily A. Kawaler…·Diane M. Simeone

This study analyzes clonal heterogeneity in human pancreatic ductal adenocarcinoma using single-cell and spatial transcriptomics, revealing transcriptional continua, clonal transitions, and spatially dispersed clones associated with metastasis.

5 citations

humanscRNA-seq

𝕏 PostBluesky